Alkem Laboratories Past Earnings Performance
Past criteria checks 5/6
Alkem Laboratories has been growing earnings at an average annual rate of 7.6%, while the Pharmaceuticals industry saw earnings growing at 14.9% annually. Revenues have been growing at an average rate of 11.4% per year. Alkem Laboratories's return on equity is 15.4%, and it has net margins of 12.5%.
Key information
7.6%
Earnings growth rate
7.6%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 11.4% |
Return on equity | 15.4% |
Net Margin | 12.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Alkem Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 126,344 | 15,732 | 30,394 | 0 |
30 Sep 23 | 123,514 | 14,329 | 29,926 | 0 |
30 Jun 23 | 119,906 | 11,433 | 30,081 | 0 |
31 Mar 23 | 115,993 | 9,842 | 29,726 | 0 |
31 Dec 22 | 111,805 | 10,208 | 27,081 | 0 |
30 Sep 22 | 107,586 | 10,917 | 26,536 | 0 |
30 Jun 22 | 104,792 | 13,051 | 25,772 | 0 |
31 Mar 22 | 106,342 | 16,456 | 25,769 | 0 |
31 Dec 21 | 103,425 | 17,780 | 22,660 | 0 |
30 Sep 21 | 100,416 | 17,033 | 22,048 | 0 |
30 Jun 21 | 96,044 | 16,311 | 21,183 | 0 |
31 Mar 21 | 88,650 | 15,850 | 19,807 | 0 |
31 Dec 20 | 87,218 | 15,338 | 21,217 | 0 |
30 Sep 20 | 85,971 | 14,648 | 21,076 | 0 |
30 Jun 20 | 84,984 | 13,636 | 20,892 | 0 |
31 Mar 20 | 83,444 | 11,271 | 20,853 | 0 |
31 Dec 19 | 81,484 | 11,057 | 20,347 | 0 |
30 Sep 19 | 78,929 | 9,262 | 19,855 | 0 |
30 Jun 19 | 75,478 | 8,098 | 19,237 | 0 |
31 Mar 19 | 73,572 | 7,605 | 18,728 | 0 |
31 Dec 18 | 70,157 | 6,602 | 17,762 | 0 |
30 Sep 18 | 68,318 | 6,293 | 17,412 | 0 |
30 Jun 18 | 67,788 | 6,955 | 17,212 | 0 |
31 Mar 18 | 63,918 | 6,309 | 16,555 | 0 |
31 Dec 17 | 60,044 | 7,009 | 15,102 | 0 |
30 Sep 17 | 57,285 | 7,626 | 14,699 | 0 |
30 Jun 17 | 55,019 | 7,248 | 14,245 | 0 |
31 Mar 17 | 56,875 | 8,920 | 13,910 | 0 |
31 Dec 16 | 56,933 | 7,732 | 13,497 | 0 |
30 Sep 16 | 54,992 | 7,267 | 12,977 | 0 |
30 Jun 16 | 52,419 | 7,108 | 9,430 | 0 |
31 Mar 16 | 49,248 | 7,416 | 11,699 | 0 |
31 Dec 15 | 47,975 | 8,189 | 15,267 | 220 |
30 Sep 15 | 44,556 | 7,227 | 15,252 | 291 |
30 Jun 15 | 40,459 | 5,781 | 11,940 | 150 |
31 Mar 15 | 37,434 | 3,916 | 9,032 | 0 |
31 Mar 14 | 31,191 | 4,353 | 10,466 | 210 |
31 Mar 13 | 24,924 | 3,838 | 8,578 | 115 |
Quality Earnings: 539523 has high quality earnings.
Growing Profit Margin: 539523's current net profit margins (12.5%) are higher than last year (9.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 539523's earnings have grown by 7.6% per year over the past 5 years.
Accelerating Growth: 539523's earnings growth over the past year (54.1%) exceeds its 5-year average (7.6% per year).
Earnings vs Industry: 539523 earnings growth over the past year (54.1%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 539523's Return on Equity (15.4%) is considered low.